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Abstract
Background: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected individuals,
which often remains undetected until cirrhosis and cirrhosis-related complications occur. Screening of high-risk
subjects in Northern Norway has revealed a relatively low prevalence in the general population (0.24%). Despite
this, late complications of HCV infection are increasing. Our object was to estimate the future prevalence and
complications of chronic HCV infection in the period 2013–2050 in a low-risk area.
Methods: We have entered available data into a prognostic Markov model to project future complications to
HCV infection.
Results: The model extrapolates the prevalence in the present cohort of HCV-infected individuals, and assumes a
stable low incidence in the projection period. We predict an almost three-fold increase in the incidence of cirrhosis
(68 per 100,000), of decompensated cirrhosis (21 per 100,000) and of hepatocellular carcinoma (4 per 100,000) by
2050, as well as a six-fold increase in the cumulated number of deaths from HCV-related liver disease (170 per
100,000 inhabitants). All estimates are made assuming an unchanged treatment coverage of approximately 15%.
The estimated numbers can be reduced by approximately 50% for cirrhosis, and by approximately one third for
the other endpoints if treatment coverage is raised to 50%.
Conclusion: These projections from a low-prevalence area indicate a substantial rise in HCV-related morbidity and
mortality in the coming years. The global HCV epidemic is of great concern and increased treatment coverage is
necessary to reduce the burden of the disease.
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Background
Chronic hepatitis C virus (HCV) infection is a major
cause of chronic liver disease and the burden of the dis-
ease is expected to increase [1–3]. Worldwide, 64–103
million people are persistently infected with HCV [4].
After acute HCV infection, between 75% and 85% of the
patients establish a chronic infection [5]. In industrial
countries, most of the patients infected with HCV will
have contracted the disease in the 1970s and 1980s.
Thus, at the beginning of the twenty-first century, a
large pool of infected patients exists, and in many coun-
tries, the cohorts of patients with chronic HCV infection
have come of age. Most infected individuals are asymp-
tomatic, but the number of patients with liver cirrhosis
and hepatocellular carcinoma (HCC) is increasing [6, 7].
Thus, 30–40 years after the start of the epidemic, the
disease is a growing burden on the health care system in
many countries.
The natural course of late-stage HCV infection is so
far unsettled. The disease increases the risk of develop-
ing liver cirrhosis and its complications such as liver
cancer and liver failure. The prognosis is highly
dependent on the rate of progression of liver fibrosis
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towards cirrhosis. Most studies have shown that the rate
of fibrosis is slow the first two decades. However, the
estimated risk of cirrhosis varies as much as 3–30% in
different populations [5, 8–10], suggesting that the
progression of the disease may not be universal but
rather depend on additional risk factors [11]. Beyond the
two first decades, the rate of fibrosis progression is
sparsely documented. One study reported that fibrosis
progression is non-linear with an estimated a risk of cir-
rhosis of 41% after 30 years [8], whereas an autopsy
study reported septal fibrosis or cirrhosis in 35% of cases
with disease duration of 25 years or longer [12].
Among patients with liver cirrhosis the annual rate of
progression to hepatic decompensation and HCC has
been described to be in the range 4–8% and 2.4–3.4%, re-
spectively [13–15]. In the absence of retrospective as well
as prospective data for the long-term progression of the
disease (>20 years), various mathematical models have
been used to reconstruct the natural course and estimate
future complications of HCV infection [1, 13, 16–18].
Even with a decline in the incidence rate after 1990, an in-
crease in the number of patients with complicated disease
and deaths from chronic HCV is expected in the coming
decades [1–3, 19, 20].
Norway is a country with a low prevalence of HCV
[21, 22]. Drug abuse is the primary transmission route,
and low age at transmission indicates a low risk for rapid
disease progression. Despite this, late complications of
HCV infection is a growing problem [23] and health
costs are expected to increase. Markov models are well
suited for simulation of chronic diseases [24], and we
have used a Markov model to estimate the future preva-
lence and complications of chronic HCV infection in the
period 2013–2050 in a low-risk area.
Methods
The study population consists of individuals included in
the Hepatitis C study in Northern Norway between 1992
and 2011 [21, 23]. In addition, we performed a registra-
tion study to assess the number of newly diagnosed indi-
viduals with HCV each year between 1998 and 2012 at
the two microbiological departments in our region.
The Hepatitis C study in Northern Norway
In 1992, a screening and medical follow-up programme
of patients with HCV infection was established in the
Health Region of Northern Norway (460.000 inhabi-
tants). In brief, general practitioners were encouraged to
screen patients with former or present risk behavior for
HCV infection. If chronic HCV infection was detected,
the general practitioners were encouraged to refer the
patient for follow-up at one of the 11 medical centers in
the region. An estimate of the year of transmission was
made for all referred patients based on either the year of
acute HCV infection or the first year of high-risk behav-
iour [23]. Liver biopsies were performed, and fibrosis
was graded (0–6) according to Ishak et al. [25]. Presence
of concomitant alcoholic liver disease was assessed by
clinical judgment.
The registry study
Individuals with a positive anti-HCV test registered at
the two microbiological departments in Northern
Norway between 1998 and 2012 were included. The year
of diagnosis was defined as the first year of a positive
anti-HCV test (ARCHITECT Anti-HCV Reagens kit.
Abbott System, Wiesbaden, Germany). Until 2004, a
positive anti-HCV test was directly confirmed with a re-
combinant immunoblot assay (RIBA HCV 3.0 SIA test,
Chiron Cooperation, Emeryville, CA, USA). Individuals
with a positive RIBA (two or more positive bands) or
indeterminate RIBA (one band) were included, while
individuals with a negative RIBA (no bands) were
excluded. The result of the HCV RNA test was recorded
if available: an in-house reverse transcriptase polymerase
chain reaction (RT-PCR) until 2004, where after the
ROCHE RT-PCR (Cobas Amplicor Hepatitis C Viral
Polymerase Chain Reaction, Roche Molecular System
Inc., Branchburg NJ, USA) was used. The ROCHE PCR
test replaced the RIBA test for confirmation of HCV in-
fection from 2005. HCV genotyping was performed as a
hybridization assay on products from the HCV RNA
PCR according to the manufacturers’ instructions
(INNO-LIPA HCV II kit, INNOGENETICS, Ghent,
Belgium). Individuals without a registered residence in
Norway were excluded. The results of HBsAg (hepatitis
B surface antigen) and anti-HIV (human immunodefi-
ciency virus) were recorded if available.
Markov model
In order to predict HCV-related morbidity and mortality
an open Markov model was constructed (Fig. 1). Of in-
fected patients, 20% were assumed to recover spontan-
eously during the first year of infection [26]. Yearly
transitions between categories were done according to
probability estimates generated from different sources.
The effect of medical treatment was modelled in three
scenarios where 0%, 15% and 50% of all patients were
assumed to receive medical treatment. Before the intro-
duction of direct acting antivirals (DAAs), treatment was
offered to eligible patients irrespective of fibrosis stage,
i.e. patients with Metavir fibrosis score F0/F1 were also
treated. The treatment coverage at this time was
approximately 15%. When the highly expensive DAAs
became available, the Norwegian national guidelines
restricted treatment to patients with fibrosis score ≥ F2.
However, since DAAs offer a simple, tolerable, short-
term and highly effective therapy, we consider an
Kileng et al. BMC Infectious Diseases  (2017) 17:624 Page 2 of 9
increased treatment coverage to 50% as possible. Recently
(March 2017), updated national guidelines recommend
treatment for all patients with genotype 1, irrespective of
fibrosis grade. Treatment of genotype 2 and 3 is still
restricted to patients with fibrosis score ≥ F2.
To estimate the rate of fibrosis progression in the
cohort, 237 records with a positive HCV RNA test, known
duration of infection, and available liver biopsy results
were entered into an ordinal regression analysis, which
can be described as a multilayer logistic regression. This
method estimates points of transition on an ordinal scale
(like the Ishak fibrosis scale). Sex, time after contraction of
the disease and HCV genotype were included as predic-
tors of Ishak fibrosis grade. Non-significant terms were re-
moved from the model leaving time after contraction and
genotype as significant predictors. Genotype 1 and 4 were
analyzed as a single group due to few observations of
genotype 4. The model predicted 70% of the observed fi-
brosis grades correctly within a margin of error of one
Ishak grade, but overestimated fibrosis grade in 13% and
underestimated in 17%. From this model, a matrix of esti-
mated probabilities of transition to a higher fibrosis grade
versus staying in the present grade for each year of infec-
tion could be constructed. It was assumed that fibrosis
development during ongoing HCV infection could only
either stay the same or change to a higher stage each year
of infection. Additional file 1 shows the regression model
in more detail. The Markov model was adjusted for geno-
types in the estimation of fibrosis progression, according
to the prevalence of the different genotypes in our popula-
tion. For transitions from Ishak 6 (compensated cirrhosis)
to more severe states, fixed probabilities were used. We
did not have exact data from Northern Norway for the
various transitions, and have thus used data from a Scot-
tish HCV population of drug-injecting abusers (as in our
study), as described by Hutchinson et al. [13], with
transition probabilities similar to that reported by others
[14, 27], as shown in Table 1. The model was corrected
for standardized mortality rate according to Norwegian
population characteristics. Non-cirrhotic subjects success-
fully treated for HCV with achieved sustained virological
response (SVR) were removed from the model. Subjects
with cirrhosis remain in risk of liver complications in spite
of SVR, and of those, 50% were retained in the model
[28]. All successfully treated subjects with decompensated
cirrhosis and HCC were kept in the model.
The overall SVR rate until 2015 was 71.3%, based on
the response of interferon-based treatment in our own
Fig. 1 The natural course of hepatitis C. The Markov model is based on simulation of transition from a given category to the next based on probability
estimates. The progression of fibrosis towards cirrhosis is based on local data, whereas most of the remaining estimated probabilities are previously
published from other cohorts. In all states of HCV, there is also an annual risk of dying from natural courses, which is implicitly included in the model
Table 1 Transition rates between different states of hepatitis C
Transition rates
From state To state Yearly transition rate Reference
Infection time Spontaneous remission 0.200 Thomas Clin Liver Dis 2005 [26]
Compensated cirrhosis Decompensated cirrhosis 0.065 Hutchinson Hepatol 2005 [13]
Decompensated cirrhosis Liver-related death 0.186 Hutchinson Hepatol 2005 [13]
Cirrhosis Hepatocellular carcinoma 0.035 Hutchinson Hepatol 2005 [13]
Hepatocellular carcinoma Death 0.605 Hutchinson Hepatol 2005 [13]
The table shows the estimated rates of transition between different states of development of hepatitis C and its complications, as used in the Markov model
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clinical practice. For individuals treated from 2015 on-
wards, the overall SVR rate was set to 90% to reflect the
improved treatment response provided by DAAs.
Entering of data into the Markov model
Figure 2 shows the actual incidence of newly diagnosed
HCV infection per year in the period from 1992 to 2012
(dark bars). After 2004, the incidence decreased to a
stable level of approximately 90 newly diagnosed cases
each year. In view of this stable number, we have pro-
jected a stable occurrence of 90 newly diagnosed cases
each year from 2013 and forwards (light bars).
HCV-positive individuals were entered into the model
at time of contraction. Since only a subgroup had a
known time of transmission, this had to be estimated for
the remaining records. First, we investigated the 402 re-
cords with known times of transmission. In 2004, all
general practitioners in the area were subject to a HCV
campaign encouraging screening of their patients with
known risk behaviour. We found an increased amount
of early diagnoses (within the first year of transmission)
in the years after this campaign compared to before
(35.5% vs. 21.3%). From these data, probability distribu-
tions could be derived in order to estimate time of con-
traction for records diagnosed before and after 2004,
respectively. Records without known time of transmis-
sion were then entered into the model using these distri-
butions as weights. From 2013 forward, the estimated
number of 90 newly diagnosed cases each year were
allocated due to the late probability distribution in order
to estimate their time of contraction.
The registration of HCV infection revealed incomplete
records regarding confirmation testing. A positive anti-
HCV test normally should be followed up with a new
blood sample for the confirmation with RIBA and/or
HCV RNA. Not all the persons with positive anti-HCV
tests had a recorded confirmation test. The starting co-
hort in the model thus consists of patients with con-
firmed HCV infection (either a positive RIBA or a
positive HCV RNA test), as well as individuals with un-
confirmed HCV (either only a positive anti-HCV or an
indeterminate RIBA). We therefore estimated the likeli-
hood of a true positive test in incomplete records in the
following way: In a sample of 326 records with a positive
anti-HCV-test where RIBA had been measured, 207 sub-
jects (63%) had a positive RIBA test, and the probability
of a true positive anti-HCV test was estimated to 0.63.
Similarly, in a sample of 14 records with an inconclusive
RIBA and a HCV RNA test, we found three individuals
with a positive HCV RNA test, and the probability of a
true positive record in case of inconclusive RIBA was es-
timated to 0.21. Summarized, individuals with either a
positive HCV RNA or RIBA were weighted 1.0, and in-
dividuals with only a positive anti-HCV test or an incon-
clusive RIBA were weighted 0.63 and 0.21, respectively.
Results
Based on the registration and subsequent weighting de-
scribed above, the estimated HCV cohort consists of
Fig. 2 Newly diagnosed hepatitis C in Northern Norway. The figure shows numbers per year of newly diagnosed individuals with hepatitis C in
Northern Norway, from the first registration in 1992 to the end of 2012 (dark bars). The estimated yearly occurrence of newly diagnosed from
2013 and forward are also shown (light bars)
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2589 individuals (positive HCV RNA or positive RIBA)
with a sex distribution of 64% men and 36% women.
Additional file 2 shows the estimation of the HCV co-
hort in more detail. The distribution between genotypes
1 through 4 was 45%, 8%, 46% and 1%, respectively. The
prevalence of HBsAg and anti-HIV was 2.3% and 1%,
respectively.
Modeled fibrosis progression
In the subgroup that was the basis for estimation of fi-
brosis progression (n = 237), the sex distribution was
the same as in the total cohort and the distribution be-
tween HCV genotypes 1 through 4 were approximately
equal to the total cohort, 45%, 10%, 44%, and 1%,
respectively. The median duration of infection was
13 years (range 0–42 years) and the mean age at liver
biopsy was 40 years. The rate of fibrosis progression was
relatively slow in the first 20–25 years of infection,
followed by an accelerated fibrosis progression, especially
in patients with genotype 3 (Fig. 3).
Markov modelling
The Markov model projects the number of patients
(per 100,000 inhabitants) in the different states of com-
pensated cirrhosis, decompensated cirrhosis and HCC
for the years 2013 to 2050, given various scenarios of
HCV treatment coverage. It estimates an almost three-
fold increase in the incidence of cirrhosis (68 per
100,000), of decompensated cirrhosis (21 per 100,000)
and of hepatocellular carcinoma (4 per 100,000) by
2050, as shown in Fig. 4a-c. Complications are expected
to reach a peak around 2040. The model predicts a six-
fold increase in the cumulated number of deaths from
HCV-related liver disease (170 per 100,000 inhabitants),
as shown in Fig. 4d. All estimates are made assuming
an unchanged treatment coverage of approximately
15%. The estimated numbers can be reduced by ap-
proximately 50% for cirrhosis, and by approximately
one third for the other endpoints if treatment coverage
were scaled up to 50%.
Discussion
In our low-risk area of HCV infection, we have esti-
mated the fibrosis progression in untreated hepatitis C.
Fibrosis develops slowly the first 20–25 years of infec-
tion, where after an accelerated fibrosis progression,
especially in genotype 3, is predicted.
Using a Markov model, we have estimated the future
complications of HCV based on the actual number of
infected individuals until the year 2012, followed by an
estimated low and stable incidence rate. The model pre-
dicts a gradual increase in HCV-related liver cirrhosis,
decompensated cirrhosis and HCC with an apparent
peak around 2040, accompanied by a gradual increase in
liver-related deaths.
Modelling
Precision of dynamic modelling for prognosis of preva-
lence, morbidity and mortality depends on the quality of
the data entered and the assumptions made. We have
used locally acquired data whenever possible. The critical
aspect in HCV pathophysiology is the progressive devel-
opment of fibrosis towards cirrhosis, and in this aspect,
our model also made use of local data. The further
Fig. 3 Development of fibrosis in hepatitis C. The figure shows the time course of distribution of estimated median fibrosis grade according to
genotype and duration of HCV disease. Estimates were derived by ordinal regression analysis of Ishak scores in 237 patients with duration of
infection and genotype as independent variables
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development from established cirrhosis is not likely to be
very different from that of other cohorts, and the use of
estimated transition rates from other studies [13] should
not affect the prognosis measurably.
Our Markov model is based on an assumed low and
stable incidence until 2050, whereas other reports esti-
mate a declining or stable incidence [2]. The observed
incidence peak in 2002–2004 in our data is probably a
result of increased focus on HCV infection among
general practitioners due to our encouragement of
diagnosis in that period.
Our cohort is relatively young, and the liver biopsy
data has a limited number of observations of severe
fibrosis (Ishak grade 4–6). Hence, the estimates
generated from these data are less precise regarding
progression through high fibrosis stages.
Published data show variable rates of liver fibrosis
progression, with 10%–40% developing cirrhosis after
20–35 years of infection [5, 8, 29]. A large systematic
review supports nonlinear fibrosis progression [8] and
other studies have shown that HCV genotype 3 is
associated with a faster fibrosis progression [30–33].
Male sex is a reported risk factor for disease
progression [5, 31]. However, we found no effect of sex
in the progression of fibrosis, which is also observed in
other studies [34].
Strengths and weaknesses
The strengths of this study are; first, we have reliable
data on the HCV-infected subjects in our health re-
gion; second, the simulated fibrosis progression in the
cohort is based on local data. However, there are ap-
parent weaknesses. First, the number of undiagnosed
HCV-infected individuals in the population is un-
known. In Sweden, a comparable country regarding
HCV epidemiology, it has been suggested that the rate
of undiagnosed HCV infection is approximately 20%
[35]. Second, incomplete records regarding confirm-
ation testing has made it necessary to estimate the
number of true positive cases, resulting in uncertainty
regarding the true prevalence. However, our estimate
of 63% true positives among those who only tested
positive for anti-HCV is not controversial compared to
another reported value of 68% true positive [36].
Moreover, the significance of RIBA-indeterminate re-
actions is unclear. Most individuals with indeterminate
RIBA have a negative HCV RNA test, which may rep-
resent previous exposure to, but spontaneous recovery
ba
c d
Fig. 4 Prediction of hepatitis C-related complications. The figure shows the predicted number of patients with cirrhosis, decompensated cirrhosis
and hepatocellular carcinoma (panels a-c), and predicted cumulated number of deaths from liver disease (panel d) in the period 2013 to 2050
according to different treatment coverage. Numbers are given per 100,000 inhabitants
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from HCV [37]. Authors have shown that approxi-
mately half of those with indeterminate RIBA have a
resolved HCV infection [38, 39]. The proportion of
RIBA-indeterminate records in our HCV population
was low, making the contribution of these records less
significant.
Third, the future incidence may be underestimated.
Most likely, transmission of HCV will still be mainly
by drug abuse, which is an ongoing problem in our re-
gion as is the case in the rest of Europe [40]. On the
other hand, the introduction of highly effective, simple,
short-term and tolerable therapies has the potential to
increase treatment coverage among people who inject
drugs. Thus, scaling up treatment in people with a
transmission risk could reduce the future incidence
and have a major impact on the HCV prevalence [41].
Fourth, it is documented that both moderate and ex-
cessive alcohol intake increase fibrosis progression in
patients with HCV [42, 43]. Presence of concomitant
excessive alcohol use was in our study assessed by clin-
ical judgment, and not by a validated questionnaire of
drinking habits. We have therefore chosen to omit al-
cohol use from the model over concerns on the quality
of the data. Several other factors have been shown to
accelerate the fibrosis progression, like co-infection
with hepatitis B virus or HIV, diabetes and obesity [9].
The prevalence of HBV or HIV co-infections in our
HCV population were low, 2.3% and 1% respectively,
and therefore not included in the model. Data regard-
ing diabetes and obesity were incomplete and neither
included in the model.
Fifth, the exact time of infection is often not known.
In individuals with unknown time of infection, we have
used the first year of high-risk behavior as the presumed
year of transmission, as others have done [30, 44, 45].
However, it has been reported that the interval between
onset of drug injection and HCV infection has length-
ened in recent years [46], which may indicate that the
duration of infection could be shorter than estimated in
our model of fibrosis progression. If so, our fibrosis
model produces a spuriously slow rate of fibrosis pro-
gression, making the prognosis relatively conservative.
Sixth, the Markov model assumes that HCC only oc-
curs when liver cirrhosis is established (Ishak 6). How-
ever, HCC can develop in lower fibrosis stages in
chronic HCV infection [47, 48]. Finally, regression of
fibrosis, cirrhosis and cirrhosis complications is pos-
sible after achieving SVR [49–51]. We do not have data
to assess the effect of SVR on fibrosis regression, i.e.
available pretreatment and post-treatment liver
biopsies, and this is another limitation of the model.
However, removing subjects achieving SVR from the
model can mimic fibrosis regression in non-cirrhotic
cases. In patients with cirrhosis, about 60% can regress
after SVR [49, 50], and much less likely in decompen-
sated cirrhosis. In patients with HCV-induced cirrhosis
who attain SVR, the risk of HCC declines, but persists
[52, 53]. To reflect that model cases with cirrhosis and
SVR still are in risk of cirrhosis complications, we have
retained 50% of these in the model.
Implications
HCV is the leading cause of chronic liver disease and
cirrhosis and is the main cause of liver transplantation
in the Western world [10]. Although the total number of
HCV-infected individuals is estimated to be stable or de-
cline in the future, an increase in liver cirrhosis, liver
cancer, hepatic decompensation and liver-related deaths
is expected in the coming years.
This assessment is underlined by the World Health
Organization (WHO) statement that the burden of
HCV disease has been largely ignored as a health pri-
ority, and the organization has developed the first-ever
global health sector strategy for addressing the viral
hepatitis pandemic [54].
To reduce the future burden of hepatitis C it is ne-
cessary to meet the challenge at three levels. First,
prophylaxis measures must focus on reducing the
transmission rate among active injection drug users. In
addition, recent guidelines suggest that treatment
should be offered to this group of individuals at high
risk of transmitting HCV due to a potential prevention
benefit [55]. Second, HCV infection among apparently
healthy subjects must be diagnosed by screening of
high-risk groups. Strategies to expand screening be-
yond high-risk groups should be considered since a
substantial proportion of infected are unaware of their
status [56]. Third, antiviral treatment has been offered
only to a small percentage of patients, as treatment is
hampered by the high cost of the new direct-acting
antiviral drugs (DAAs). Based on the unpredictable
course of liver fibrosis at the individual level, delaying
treatment of patients with early fibrosis stages will in-
crease the risk of liver complications [11]. DAAs has
the potential to reduce the future burden of disease of
HCV, but this is restricted by the current treatment levels
[19]. In spite of the high costs of DAAs, several studies
show that interferon-free regimens are cost-effective
compared to interferon-based regimens [57–61].
Conclusion
Based on the registration of patients with HCV in a
low risk area, we estimate a relatively slow fibrosis pro-
gression within the first 20–25 years of infection,
followed by an accelerated fibrosis progression, espe-
cially in subjects with HCV genotype 3. This may have
important implications in the clinical management of
patients infected with genotype 3.
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Furthermore, we estimate a gradual increase in fu-
ture complications with an estimated peak around
2040. The projected scenario implies a substantial in-
crease in HCV-related morbidity and mortality in the
coming years. An increased number of patients need
to be treated to have an impact on the future burden
of HCV disease.
Additional files
Additional file 1: Ordinal regression model for estimating fibrosis grade
according to duration of infection. (DOCX 19 kb)
Additional file 2: Estimated HCV cohort 1992–2012. The file describes
how we estimated our HCV cohort. (DOCX 15 kb)
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